-

10:21:42 PM

OCGN Stock News

OCGN - Ocugen Inc

10/19/21 8:34 AM

Nasdaq : OCGN

conferencesclinical trial

Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its head of

RHEA-AI

neutral

10/16/21 9:42 AM

Nasdaq : OCGN

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation

RHEA-AI

very positive

09/23/21 4:08 PM

Nasdaq : OCGN

conferences

Ocugen, Inc. to Participate in Fireside Chat at the Cantor Virtual Global Healthcare Conference

Ocugen, Inc . (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that its Chairman, CEO, and

RHEA-AI

neutral

09/17/21 4:52 PM

Nasdaq : OCGN

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation

RHEA-AI

very positive

09/07/21 5:22 PM

Nasdaq : OCGN

conferences

Ocugen, Inc. to Present at Upcoming Citi and H.C. Wainwright Investment Conferences

Ocugen, Inc . (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in

RHEA-AI

neutral

08/20/21 4:34 PM

Nasdaq : OCGN

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation

RHEA-AI

very positive

08/06/21 7:32 AM

Nasdaq : OCGN

earnings

Ocugen Provides Business Update and Second Quarter 2021 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Rolling regulatory submission to Health Canada completed and review process initiated; U.S. FDA talks continue Multiple milestones achieved across regulatory and supply chain to support potential commercialization of pipeline assets The Company

RHEA-AI

neutral

07/30/21 8:45 AM

Nasdaq : OCGN

conferencesearnings

Ocugen to Host Conference Call on Friday, August 6 at 8:30 a.m. ET to Discuss Second Quarter 2021 Financial Results and Provide Business Update

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a

RHEA-AI

neutral

07/16/21 4:59 PM

Nasdaq : OCGN

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation

RHEA-AI

very positive

07/15/21 7:34 AM

Nasdaq : OCGN

Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN™

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it had initiated a

RHEA-AI

neutral

1 2 3 4 5 6 Next

OCGN Data:

IndustrySanitary Paper Product Manufacturing
Websiteocugen.com
CeoShankar Musunuri
Security nameOcugen Inc
Issue typecs
SectorManufacturing
Sic code3842
Employees15
Tags
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Sanitary Paper Product Manufacturing
Address5 Great Valley Pkwy Ste 160
StatePennsylvania
CityMalvern
Zip19355
CountryUS
Phone14843284698

OCGN Description:

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug - "one to many" and its novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The Company is co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.